Weekly Analysts’ Ratings Changes for Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (NYSE: TMO) recently received a number of ratings updates from brokerages and research firms:

  • 2/3/2025 – Thermo Fisher Scientific had its price target raised by analysts at Scotiabank from $605.00 to $650.00. They now have a “sector perform” rating on the stock.
  • 2/3/2025 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $667.00 price target on the stock, up previously from $650.00.
  • 1/31/2025 – Thermo Fisher Scientific had its price target raised by analysts at Wells Fargo & Company from $660.00 to $680.00. They now have an “overweight” rating on the stock.
  • 1/31/2025 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $647.00 to $678.00. They now have an “overweight” rating on the stock.
  • 1/31/2025 – Thermo Fisher Scientific had its price target raised by analysts at Citigroup Inc. from $600.00 to $650.00. They now have a “neutral” rating on the stock.
  • 1/31/2025 – Thermo Fisher Scientific had its price target raised by analysts at UBS Group AG from $700.00 to $715.00. They now have a “buy” rating on the stock.
  • 1/14/2025 – Thermo Fisher Scientific was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
  • 1/13/2025 – Thermo Fisher Scientific had its price target lowered by analysts at Morgan Stanley from $670.00 to $647.00. They now have an “overweight” rating on the stock.
  • 1/10/2025 – Thermo Fisher Scientific was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $630.00 price target on the stock.
  • 1/6/2025 – Thermo Fisher Scientific was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
  • 12/23/2024 – Thermo Fisher Scientific is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $605.00 price target on the stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $532.58 on Tuesday. The firm has a market cap of $203.71 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $548.51 and its two-hundred day simple moving average is $569.90.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,125 shares of company stock valued at $11,231,699. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of TMO. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Thermo Fisher Scientific by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company’s stock valued at $1,259,450,000 after purchasing an additional 257,462 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $7,471,000. Worldquant Millennium Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 167.2% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 205,529 shares of the medical research company’s stock valued at $106,922,000 after acquiring an additional 128,611 shares during the period. Waverly Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 6.7% in the fourth quarter. Waverly Advisors LLC now owns 21,523 shares of the medical research company’s stock valued at $11,197,000 after acquiring an additional 1,346 shares during the period. Finally, Wesleyan Assurance Society raised its stake in shares of Thermo Fisher Scientific by 2,305.1% in the fourth quarter. Wesleyan Assurance Society now owns 7,095 shares of the medical research company’s stock valued at $3,691,000 after acquiring an additional 6,800 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.